RSNA 2023: Bracco Diagnostics Inc.

Bracco Announces Long-Term Strategic Partnership with ulrich medical for Syringeless Magnetic Resonance Injectors

Wed, 22 Nov 2023 14:01:00 -0500

The private label arrangement will bring a new syringeless magnetic resonance (MR) injector to the U.S. 510(k) premarket notification has been submitted to the U.S. Food and Drug Administration

Bracco Diagnostics Showcases Innovation and Collaborative Vision at RSNA 2023 Annual Meeting

Mon, 16 Oct 2023 08:00:00 -0400

--Leaders in Radiology Will Share Insights on VUEWAY® (gadopiclenol) solution for injection After the First Year of Use in the U.S.--

Bracco Elevates Next Generation of Radiologists, Announces Recipients of the 2022 “Leaders on the Horizon” Residency Program

Wed, 09 Nov 2022 09:28:00 -0500

Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception

Bracco Features its Mission of ‘No Compromise in MRI’ at the 2022 Radiological Society of North America Annual Congress

Mon, 17 Oct 2022 08:00:00 -0400

Bracco’s attendance at RSNA follows FDA approval of Gadopiclenol injection, a novel macrocyclic high-relaxivity gadolinium-based contrast agent which will be commercialized as VUEWAYTM (gadopiclenol) injection by Bracco^{i, ii}

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco

Wed, 21 Sep 2022 14:29:00 -0400

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical useⁱ